Boston Scientific Mesh Settlement Results in $189M Payments to Resolve State Attorneys General Lawsuit

As part of a settlement to resolve claims it withheld information about risks associated transvaginal mesh products and engaged in deceptive advertising nationwide, Boston Scientific has agreed to pay $188.6 million to various 47 states and the District of Columbia.

The Boston Scientific mesh settlement was confirmed this week by several state attorneys general, including New York Attorney General Letitia James, who issued a press release detailing the agreement.

Over the past decade, problems have emerged with the design of several surgical mesh products sold by Boston Scientific and other manufacturers for treatment of pelvic organ prolapse and female stress urinary incontinence. The mesh products have been linked to reports of painful and devastating injuries, including infections, erosion of the mesh into the vagina and organ perforation.

|
|

In April 2019, the FDA ordered all medical device manufacturers to cease making and selling transvaginal mesh, after determining the health risks outweighed the benefits, which could be achieved via other means.

More than 100,000 product liability lawsuits have been brought by individual women who experienced painful and debilitating complications from transvaginal mesh complications sold by Boston Scientific, Johnson & Johnson, Bard, and companies, which have paid out billions in individual settlements to resolve personal injury and wrongful death claims in recent years.

This latest deal resolves allegations raised in a complaint (PDF) filed against Boston Scientific on March 23, the same day the settlement was announced, which accused the company of misrepresenting its transvaginal mesh products by failing to provide adequate warnings to the medical community and to patients about the safety risks.

In addition to the nearly $189 million settlement, Boston Scientific has agreed to put in place new marketing training and to reform how it does clinical studies.

“While Boston Scientific was putting income before the health of people in need of care, women were put in danger,” James said in the press release. “My office will never waver in its efforts to hold companies accountable for risking the health of its consumers.”

The settlement agreement does not include an admission of guilt by Boston Scientific.

Johnson & Johnson reached a similar settlement with 41 states and the District of Columbia in October 2019, agreeing to pay nearly $117 million to resolve the states’ allegations.

The litigation over transvaginal surgical mesh has been one of the largest mass torts in U.S. history, with tens of thousands of women filing cases nationwide. Over the past few years, various different manufacturers have reached transvaginal mesh settlements to resolve most of the claims pending, but new claims continue to be filed by women who experience problems with the products.

Written by: Irvin Jackson

Senior Legal Journalist & Contributing Editor

Irvin Jackson is a senior investigative reporter at AboutLawsuits.com with more than 30 years of experience covering mass tort litigation, environmental policy, and consumer safety. He previously served as Associate Editor at Inside the EPA and contributes original reporting on product liability lawsuits, regulatory failures, and nationwide litigation trends.




0 Comments


This field is for validation purposes and should be left unchanged.

Share Your Comments

This field is hidden when viewing the form
I authorize the above comments be posted on this page
Post Comment
Weekly Digest Opt-In

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

MORE TOP STORIES

A new lawsuit against Roblox alleges that the platform’s inadequate safety measures enabled multiple sexual predators to exploit a five-year-old girl.
Breast mesh implants promoted as internal bras are now under scrutiny, following studies and FDA warnings linking the devices to infections, implant loss, and surgical failure. Lawsuits are being investigated for women who suffered complications after reconstruction or augmentation procedures involving products like GalaFLEX, Phasix, Strattice, and AlloDerm.
Dupixent users are coming forward with accounts of devastating cancer diagnoses, saying the popular eczema drug masked early warning signs of cutaneous T-cell lymphoma. As the FDA investigates and the first lawsuit is filed, researchers warn Dupixent may unmask or accelerate hidden cancers, raising urgent questions about its long-term safety.